Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones

RIGEL PHARMACEUTICALS INC

Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.
Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.
Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.
VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
Deal subject to HSR waiting period expiration or termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RIGEL PHARMACEUTICALS INC entered into Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. valued at $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest (effective 2026-05-11).

Action: entry
Agreement: license
Counterparty: Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.
Value: $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest
Effective: 2026-05-11

Exact text from the filing

On May 11, 2026, Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") entered into a License Agreement (the "Agreement") with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the "Licensors").

View on SEC.gov

Browse all material agreements →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001034842-26-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.